Medications for Ulcerative Colitis

13 results

  • asacol

    (mesalamine)
    State of Florida DOH Central Pharmacy
    Asacol tablets are indicated for treating mildly to moderately active ulcerative colitis and for maintaining remission of the condition.

  • cyltezo

    (adalimumab-adbm)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

  • hulio

    (adalimumab-fkjp)
    Mylan Specialty L.P.
    HULIO is indicated for reducing signs and symptoms, and improving function in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and children over 2 years.

  • inflectra

    (infliximab-dyyb)
    Pfizer Laboratories Div Pfizer Inc
    INFLECTRA is indicated for treating moderately to severely active Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults and pediatric patients aged 6 and older, particularly in cases unresponsive to conventional therapies.

  • omvoh

    (mirikizumab-mrkz)
    Eli Lilly and Company
    OMVOH is indicated for treating moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease in adults.

  • rayos

    (prednisone)
    Horizon Therapeutics USA, Inc.
    RAYOS is indicated for severe allergic conditions, various dermatologic and endocrine diseases, gastrointestinal disorders (like Crohn's and ulcerative colitis), hematologic issues, neoplasms, nervous system conditions (such as multiple sclerosis), certain ophthalmic diseases, organ transplant rejection, pulmonary disorders, renal conditions, rheumatologic ailments, and specific infectious diseases.

  • simponi

    (golimumab)
    Janssen Biotech, Inc.
    SIMPONI is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (with methotrexate), active psoriatic arthritis (alone or with methotrexate), active ankylosing spondylitis, and moderately to severely active ulcerative colitis in patients with corticosteroid dependence or inadequate response to previous therapies.

  • skyrizi

    (Risankizumab-rzaa)
    AbbVie Inc.
    SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis in adults.

  • tremfya

    (Guselkumab)
    Janssen Biotech, Inc.
    TREMFYA is indicated for adult patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, specifically those who are candidates for systemic therapy or phototherapy.

  • uceris

    (budesonide)
    Salix Pharmaceuticals, Inc.
    UCERIS rectal foam is indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis that extends up to 40 cm from the anal verge.